Investigational Drug Information for Tauroursodeoxycholic acid
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Tauroursodeoxycholic acid?
Tauroursodeoxycholic acid is an investigational drug.
There have been 22 clinical trials for Tauroursodeoxycholic acid.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2012.
The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are Washington University School of Medicine, Amylyx Pharmaceuticals Inc., and IRCCS Policlinico S. Matteo.
There are three hundred and forty US patents protecting this investigational drug and two international patents.
Summary for Tauroursodeoxycholic acid
| US Patents | 340 |
| International Patents | 2,468 |
| US Patent Applications | 1,527 |
| WIPO Patent Applications | 587 |
| Japanese Patent Applications | 266 |
| Clinical Trial Progress | Phase 3 (2012-12-01) |
| Vendors | 42 |
Recent Clinical Trials for Tauroursodeoxycholic acid
| Title | Sponsor | Phase |
|---|---|---|
| The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis. | The First Affiliated Hospital with Nanjing Medical University | Early Phase 1 |
| Targeting ER Stress in Vascular Dysfunction | Colorado State University | Early Phase 1 |
| Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS | Bruschettini S.r.l. | Phase 3 |
Clinical Trial Summary for Tauroursodeoxycholic acid
Top disease conditions for Tauroursodeoxycholic acid
Top clinical trial sponsors for Tauroursodeoxycholic acid
US Patents for Tauroursodeoxycholic acid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tauroursodeoxycholic acid | See Plans and Pricing | Measurement method for human pancreatic lipase activity | ASAHI KASEI PHARMA CORPORATION (Tokyo, JP) | See Plans and Pricing |
| Tauroursodeoxycholic acid | See Plans and Pricing | 17-hydroxyprogesterone ester-containing oral compositions and related methods | Lipocine Inc. (Salt Lake City, UT) | See Plans and Pricing |
| Tauroursodeoxycholic acid | See Plans and Pricing | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use | Vivus, Inc. (Campbell, CA) | See Plans and Pricing |
| Tauroursodeoxycholic acid | See Plans and Pricing | Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tauroursodeoxycholic acid
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tauroursodeoxycholic acid | China | CN105164273 | 2033-04-18 | See Plans and Pricing |
| Tauroursodeoxycholic acid | European Patent Office | EP2987867 | 2033-04-18 | See Plans and Pricing |
| Tauroursodeoxycholic acid | Spain | ES2654437 | 2033-04-18 | See Plans and Pricing |
| Tauroursodeoxycholic acid | Japan | JP6064041 | 2033-04-18 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
